# Entrectinib in NTRK fusion-positive solid tumours: integrated analysis of three trials

Source: https://onco.cc/key-papers/paper-doebele-entrectinib-ntrk-lancet-oncol-2020/  
OnCo record `paper-doebele-entrectinib-ntrk-lancet-oncol-2020` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Entrectinib, a TRK and ROS1 inhibitor that enters the brain, shrank tumours in more than half of patients with NTRK fusion-positive cancers of ten types and controlled brain metastases, leading to a tumour-agnostic approval alongside larotrectinib.

## Summary

Integrated analysis of 54 adults with NTRK fusion-positive solid tumours from the ALKA-372-001, STARTRK-1 and STARTRK-2 trials treated with entrectinib.

Objective response was 57 percent with a median duration of response of 10 months and intracranial response in half of the patients with brain metastases; toxicity included weight gain, dizziness and dysgeusia.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: The Lancet Oncology
- Year: 2020
- DOI: 10.1016/S1470-2045(19)30691-6
- Authors: Doebele RC, Drilon A, Paz-Ares L, et al.
- Findings: Objective response 57 percent; median duration of response 10 months.; Intracranial response in 50 percent of patients with brain metastases.
- What it means: Entrectinib is an approved tumour-agnostic TRK inhibitor with an advantage in patients with brain metastases, and it is also approved for ROS1-positive lung cancer.
- Caveats: Small pooled population; median progression-free survival 11 months.

## Sources

- Lancet Oncol 2020: https://doi.org/10.1016/S1470-2045(19)30691-6
- PubMed: https://pubmed.ncbi.nlm.nih.gov/31838007/

## Connected records

- cancers: [NTRK fusion-positive non-small-cell lung cancer](https://onco.cc/cancers/ntrk-fusion-nsclc/)
- drugs: [Entrectinib](https://onco.cc/drugs/entrectinib/)
- journals: [The Lancet Oncology](https://onco.cc/journals/lancet-oncology/)

---
JSON: https://onco.cc/api/v1/entities/paper-doebele-entrectinib-ntrk-lancet-oncol-2020.json